Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy

Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy

Introduction: Rituximab is a first-line treatment for primary membranous nephropathy (pMN), with proven efficacy and safety. The use of monoclonal antibodies such as rituximab can lead to the formation of antidrug antibodies that may interfere with the therapeutic response. In pMN, anti-rituximab an...

Full description

Saved in:
Bibliographic Details
Main Authors: Marco Allinovi, Maxime Teisseyre, Matteo Accinno, Cecilia Finocchi, Vincent L.M. Esnault, Marion Cremoni, Tommaso Mazzierli, Daniela Lazzarini, Micaela Anna Casiraghi, Céline Fernandez, Kévin Zorzi, Vesna Brglez, Lorenzo Cosmi, Andrea Matucci, Leonardo Caroti, Giulia Antognoli, Calogero Lino Cirami, Alessandra Vultaggio, Barbara Seitz-Polski
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Kidney International Reports
Subjects:
antidrug antibody
anti-rituximab antibody
immunogenicity
membranous nephropathy
neutralizing antibodies
rituximab
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024925002840
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S2468024925002840

Similar Items